One of the key takeaways from BIO-Europe Spring 2020, which was held virtually March 23-27, was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public. 

Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

Alameda, Calif.-based Exelixis inked a collaboration, option and license deal with India’s Aurigene Discovery Technologies Ltd., which focuses on oncology and inflammatory diseases.

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.

The IASLC, Guardant Health, the Global Lung Cancer Coalition and AstraZeneca announced the Lung Ambition Alliance, a new partnership to eliminate lung cancer as a cause of death.

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.

OncoSec Medical Incorporated and Duke University School of Medicine announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary Tavoplus (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system.

San Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.